UK markets open in 3 hours 4 minutes
NIKKEI 225
25,974.80 -447.25 (-1.69%) HANG SENG
17,190.88 +25.01 (+0.15%) CRUDE OIL
81.09 -0.14 (-0.17%) GOLD FUTURES
1,670.70 +2.10 (+0.13%) DOW
29,225.61 -458.13 (-1.54%) BTC-GBP
17,452.61 -203.46 (-1.15%)
Newron Pharmaceuticals S.p.A. (0QOI.L)
LSE - LSE Delayed price. Currency in CHF
Add to watchlist
At close: 04:56PM BST
| Previous close | 0.0000 |
| Open | 1.3300 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 1.3300 - 1.3300 |
| 52-week range | 1.3300 - 1.3300 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 179,266 |
| Beta (5Y monthly) | 0.60 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.8500 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Newron provides H1 2022 results and updates on R&D and business activities
MILAN, September 15, 2022--Newron Pharmaceuticals today announces its half-year 2022 financial results and operational highlights and updates its R&D and business activities.
- Business Wire
Newron Extends Senior Management Team and Strengthens Commitment to ESG
MILAN, July 01, 2022--Newron extends Senior Management team and strengthens its commitment to ESG by appointing Filippo Moriggi as Vice President of Operations.
- Business Wire
Newron presents encouraging interim results for evenamide in patients with Treatment-Resistant Schizophrenia (TRS) at the 33rd CINP Hybrid World Congress of Neuropsychopharmacology
MILAN, Italy, June 07, 2022--Newron presents encouraging interim results for evenamide in patients with Treatment-Resistant Schizophrenia (TRS). Conference call today at 9 AM ET.
© 2022 Yahoo. All rights reserved.
